title: Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases.
abstract: Thrombotic microangiopathy (TMA) has been described as a complication of bone marrow or stem cell transplantation. It is usually associated with high dose therapy for autologous transplantation or myeloablative conditioning in the allogeneic setting. Here we report three cases of TMA after reduced intensity conditioning and allogeneic peripheral blood stem cell transplantation. All three patients had high dose Melphalan therapy with autologous stem cell support preceding the allogeneic transplantation for several weeks, which may have contributed to endothelial damage and subsequent development of TMA.
authors.affiliation: Department of Medicine V, University of Heidelberg, Heidelberg, Germany. martin_kornacker@med.uni-heidelberg.de
authors.forename: M
authors.initials: M
authors.lastname: Kornacker
authors.forename: T
authors.initials: T
authors.lastname: Luft
authors.forename: A D
authors.initials: AD
authors.lastname: Ho
authors.forename: H-J
authors.initials: HJ
authors.lastname: Schaefer
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D004730:Endothelium, Vascular / Q000473:pathology; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology*; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications* / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D011697:Purpura, Thrombotic Thrombocytopenic / Q000209:etiology*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents